Biggest Clinical Wins of the Week: Large-Cap Edition

See which big biotech and pharmaceutical companies got the best clinical results for the week ending March 28.

Apr 2, 2014 at 2:30PM

Last week, big pharma icons Pfizer (NYSE:PFE), and Novartis (NYSE:NVS) stayed just even with the broad market despite posting some great news from the clinic. Celgene (NASDAQ:CELG) announced some results that could quickly lead to a revenue-boosting label expansion. Even great news from the biotechnology giant wasn't enough to avoid the industrywide sell-off last week.

^SPX Chart

^SPX data by YCharts

Moving quickly
Almost immediately following FDA approval for Otezla in psoriatic arthritis, Celgene posted trial data supporting its case for the broader psoriasis population. Patients receiving Otezla for 52 weeks demonstrated a mean psoriasis area and severity index improvement of 81%. Patients with psoriasis in difficult-to-treat areas, like the fingernails and scalp, also demonstrated positive response.

Assuming approval for the the larger plaque psoriasis population, potential sales estimates for the oral PDE4 inhibitor vary. Celgene suggests between $1.5 billion and $2 billion by 2017. EvaluatePharma's consensus puts peak sales at just $1 billion. With 2013 revenue of just $6.5 billion, even the low-end estimates represent a big win if the drug is approved.

While analysts can't agree on Otezla's sales potential, most think the competition will be fierce. AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN), and Pfizer aren't about to let Otezla take market share from Humira and Enbrel without a fight. They have plenty of sales and marketing muscle to make a successful launch difficult for Celgene.

Luckily, Otezla brings some important features to the table. Patients suffering from sore injection sites ought to be interested in a well-tolerated pill. At just $22,500 per patient per year, Otezla is priced lower than most biologics. Considering the savings, government and private payers have good reasons to give patients the option. 

Just better
Pfizer posted three big clinical wins last week. Its next-generation cholesterol drug, bococizumab, met its primary endpoint in a phase 2b trial. A week earlier, it was Amgen posting great results with its PCSK9 program. Pfizer also hit the mark in a phase 3 Genotropin growth hormone study. Children 24 to 30 months old and considered too small for their age who took the drug grew faster than the control group.

The biggest win for Pfizer last week put Xalkori a step closer to expanding into first-line lung cancer. In a head-to-head test with standard platinum-based chemotherapy regimens, Xalkori was better at prolonging progression-free survival.

The most troubling part of the announcement was that it provided no figures. Pfizer didn't quantify just how much longer it prolonged survival or what percentage of patients responded. Data from this study will be submitted for presentation at an undisclosed future medical meeting. Investors want to keep their eyes open for that data and recognize that approval is by no means assured.

The oral ALK inhibitor won an accelerated approval in 2011 for treatment of metastatic lung cancer with ALK-positive tumors. It isn't the company's biggest seller, but it is its fastest-growing revenue stream. Xalkori sales jumped 129% last year to $282 million. Analysts estimate a label expansion to first-line treatment could raise it to blockbuster status, if competing ALK inhibitors from Novartis, Roche, and Ariad don't invade its market.

Majority response
Hot on the heels of Pfizer's Xalkori release, the New England Journal of Medicine published interim results from a phase 1 study of Novartis' ALK inhibitor, ceritinib. The overall response rate was a whopping 58%, with progression-free survival of seven months.

One of the problems with Xalkori is that many patients develop a resistance that leaves them short on treatment options. If approved, ceritinib could become a powerful competitor. More than two-thirds of the patients in the trial had progressed after or during Xalkori treatment. About 56% of those patients responded to ceritinib.

This was just an early stage trial, but Novartis intends to include these results in a new drug application. The FDA has already granted ceritinib a Breakthrough Therapy designation, and I think its chances are good. Xalkori resistant lung cancer is effectively a life-threatening condition with unmet need. Given these results, it looks like ceritinib fits the bill.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers